392 related articles for article (PubMed ID: 20645852)
1. The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome.
Jornayvaz FR; Samuel VT; Shulman GI
Annu Rev Nutr; 2010 Aug; 30():273-90. PubMed ID: 20645852
[TBL] [Abstract][Full Text] [Related]
2. Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals.
Rabøl R; Petersen KF; Dufour S; Flannery C; Shulman GI
Proc Natl Acad Sci U S A; 2011 Aug; 108(33):13705-9. PubMed ID: 21808028
[TBL] [Abstract][Full Text] [Related]
3. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome.
Petersen KF; Dufour S; Savage DB; Bilz S; Solomon G; Yonemitsu S; Cline GW; Befroy D; Zemany L; Kahn BB; Papademetris X; Rothman DL; Shulman GI
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12587-94. PubMed ID: 17640906
[TBL] [Abstract][Full Text] [Related]
4. Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly.
Flannery C; Dufour S; Rabøl R; Shulman GI; Petersen KF
Diabetes; 2012 Nov; 61(11):2711-7. PubMed ID: 22829450
[TBL] [Abstract][Full Text] [Related]
5. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Højlund K
Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome: effects of n-3 PUFAs on a model of dyslipidemia, insulin resistance and adiposity.
Lombardo YB; Hein G; Chicco A
Lipids; 2007 May; 42(5):427-37. PubMed ID: 17476547
[TBL] [Abstract][Full Text] [Related]
7. The metabolic basis of atherogenic dyslipidemia.
Vinik AI
Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
[TBL] [Abstract][Full Text] [Related]
8. Fatty liver disease in obese children--relation to other metabolic risk factors.
Volovelsky O; Weiss R
Int J Pediatr Obes; 2011 Sep; 6 Suppl 1():59-64. PubMed ID: 21905818
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Simon TG; Corey KE; Chung RT; Giugliano R
Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
[TBL] [Abstract][Full Text] [Related]
10. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease.
Gaggini M; Morelli M; Buzzigoli E; DeFronzo RA; Bugianesi E; Gastaldelli A
Nutrients; 2013 May; 5(5):1544-60. PubMed ID: 23666091
[TBL] [Abstract][Full Text] [Related]
11. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
[TBL] [Abstract][Full Text] [Related]
12. Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease.
Smith AG; Muscat GE
Int J Biochem Cell Biol; 2005 Oct; 37(10):2047-63. PubMed ID: 15922648
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease.
Akhtar DH; Iqbal U; Vazquez-Montesino LM; Dennis BB; Ahmed A
J Clin Transl Hepatol; 2019 Dec; 7(4):362-370. PubMed ID: 31915606
[TBL] [Abstract][Full Text] [Related]
14. Prolonged PM2.5 exposure elevates risk of oxidative stress-driven nonalcoholic fatty liver disease by triggering increase of dyslipidemia.
Xu MX; Ge CX; Qin YT; Gu TT; Lou DS; Li Q; Hu LF; Feng J; Huang P; Tan J
Free Radic Biol Med; 2019 Jan; 130():542-556. PubMed ID: 30465824
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome.
Lim S; Taskinen MR; Borén J
Obes Rev; 2019 Apr; 20(4):599-611. PubMed ID: 30589487
[TBL] [Abstract][Full Text] [Related]
16. Fructose as a key player in the development of fatty liver disease.
Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms underlying the beneficial effect of soy protein in improving the metabolic abnormalities in the liver and skeletal muscle of dyslipemic insulin resistant rats.
Oliva ME; Chicco A; Lombardo YB
Eur J Nutr; 2015 Apr; 54(3):407-19. PubMed ID: 24898793
[TBL] [Abstract][Full Text] [Related]
18. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.
Lomonaco R; Ortiz-Lopez C; Orsak B; Webb A; Hardies J; Darland C; Finch J; Gastaldelli A; Harrison S; Tio F; Cusi K
Hepatology; 2012 May; 55(5):1389-97. PubMed ID: 22183689
[TBL] [Abstract][Full Text] [Related]
19. Liver and insulin resistance: New wine in old bottle!!!
Patel BM; Goyal RK
Eur J Pharmacol; 2019 Nov; 862():172657. PubMed ID: 31499040
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis of insulin resistance in skeletal muscle.
Abdul-Ghani MA; DeFronzo RA
J Biomed Biotechnol; 2010; 2010():476279. PubMed ID: 20445742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
